VBL Therapeutics' brain cancer drug succeeds in mid-stage study

March 25, 2015 11:29 AM

18 0

(Reuters) - Israel-based VBL Therapeutics said a mid-stage study of its experimental brain cancer drug met the main goal of increasing overall survival.

The drug developer's shares were up 20 percent at $6.70 in premarket trade on Wednesday.

Also read: ZTE shares rise in Hong Kong after clarification of U.S. bill impact

Read more

To category page